Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · December 30, 2021

Personalized Therapy vs Physician's Choice for Patients With Residual Triple-Negative Breast Cancer

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer
J. Clin. Oncol 2021 Dec 15;[EPub Ahead of Print], BP Schneider, G Jiang, TJ Ballinger, F Shen, C Chitambar, R Nanda, C Falkson, FC Lynce, C Gallagher, C Isaacs, M Blaya, E Paplomata, R Walling, K Daily, R Mahtani, MA Thompson, R Graham, ME Cooper, DC Pavlick, LA Albacker, J Gregg, JP Solzak, YH Chen, CL Bales, E Cantor, BA Hancock, N Kassem, P Helft, B O'Neil, AMV Storniolo, S Badve, KD Miller, M Radovich

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading